TG Therapeutics, Inc.
TGTX
$29.45
$0.6752.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.82% | -4.97% | 84.52% | 44.55% | 154.47% |
| Total Depreciation and Amortization | -74.21% | -72.67% | -67.77% | -60.57% | -36.14% |
| Total Amortization of Deferred Charges | -44.91% | -32.55% | -14.79% | 5.43% | 23.90% |
| Total Other Non-Cash Items | 66.26% | 28.89% | 14.16% | -1.29% | -14.13% |
| Change in Net Operating Assets | -174.07% | -143.21% | -29.10% | 5.02% | -141.99% |
| Cash from Operations | -187.18% | -400.88% | -28.98% | 33.24% | 142.32% |
| Capital Expenditure | -- | -- | -- | -700.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 87.44% | 91.36% | 98.04% | -693.24% | -319.23% |
| Cash from Investing | 87.30% | 91.23% | 97.95% | -693.65% | -319.28% |
| Total Debt Issued | -- | -- | 879.26% | 879.26% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 115.90% | -98.05% | -98.09% | -99.28% | -98.81% |
| Repurchase of Common Stock | -2,175,700.00% | -1,488,200.00% | -875,900.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -611.20% | -586.40% | 100.00% |
| Cash from Financing | 20,402.12% | 157.84% | 76.78% | 85.00% | -99.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 428.27% | 304.22% | 1,029.31% | 9.45% | 71.86% |